Exbio — Research products — Antibodies — Microbiology and virology — Anti-HIV protease (HIV-1/HIV-2) Purified

Anti-HIV protease (HIV-1/HIV-2) Purified

Anti-HIV protease (HIV-1/HIV-2) Purified
Regulatory status
RUO
Antigen
HIV protease (HIV-1/HIV-2)
Clone
1696
Format
Purified
Reactivity
Human Immunodeficiency Virus
Application
ELISA, WB
Variant
0.1 mg
11-302-C100
In stock
140.00 USD
0.025 mg
11-302-C025
Delivery 1 week
70.00 USD
Variant
0.1 mg
11-302-C100
In stock
140.00 USD
0.025 mg
11-302-C025
Delivery 1 week
70.00 USD
Contact distributor
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
Application
ELISA, WB
Application details
Western blotting: Recommended dilution: 0.5 μg/ml.
Reactivity
Human Immunodeficiency Virus
Immunogen
Bacterially expressed full-length HIV-1 protease
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
HIV-1 PR, HIV-2 PR
Antigen description
The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.
11-302 DB
Dot blot analysis of recombinant HIV protease. The total amount of recombinant HIV-protease spotted on the nitrocellulose membrane are indicated in left column. Lane 1: anti-HIV protease (1696); 0.2 μg/ml Lane 2: anti-HIV protease (1696); 1.0 μg/ml Lane 3: anti-HIV protease (1696); 2.0 μg/ml

General references:

Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46(51):14854-64.
PubMed
Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9(1):181
PubMed
Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71(4):298-305.
PubMed
Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7.
PubMed

Product specific references:

O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23(4):764-72.
PubMed
Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78(3):275-7. Epub 2008 Feb 20.
PubMed
Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8(12):2686-96.
PubMed
Variant
0.1 mg
11-302-C100
In stock
140.00 USD
0.025 mg
11-302-C025
Delivery 1 week
70.00 USD
Variant
0.1 mg
11-302-C100
In stock
140.00 USD
0.025 mg
11-302-C025
Delivery 1 week
70.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product